RESUMEN
Cannabis is often used by people with HIV (PWH) for pain, yet study results are inconsistent regarding whether and how it affects pain. This study examines whether greater cannabis use frequency is associated with lower pain interference and whether cannabis use modifies the association of pain severity and pain interference among 134 PWH with substance dependence or a lifetime history of injection drug use. Multi-variable linear regression models examined the association between past 30-day cannabis use frequency and pain interference. Additional models evaluated whether cannabis use modified the association between pain severity and pain interference. Cannabis use frequency was not significantly associated with pain interference. However, in a model with interaction between cannabis use frequency and pain severity, greater cannabis use frequency attenuated the strength of the association between pain severity and pain interference (p = 0.049). The adjusted mean difference (AMD) in pain interference was +1.13, + 0.81, and +0.05 points for each 1-point increase in pain severity for those with no cannabis use, 15 days of use, and daily use, respectively. These findings suggest that attenuating the impact of pain severity on pain-related functional impairment is a potential mechanism for a beneficial role of cannabis for PWH.
Asunto(s)
Cannabis , Infecciones por VIH , Trastornos Relacionados con Sustancias , Humanos , Infecciones por VIH/complicaciones , Infecciones por VIH/epidemiología , Dolor/tratamiento farmacológico , Dolor/epidemiologíaRESUMEN
BACKGROUND: Information on individual mental healthcare costs and utilization patterns in Italy is scant. We analysed the use and the annual costs of community mental health services (MHS) in an Italian local health authority (LHA). Our aims are to compare the characteristics of patients in the top decile of costs with those of the remaining 90%, and to investigate the demographic and clinical determinants of costs. METHODS: This retrospective study is based on administrative data of adult patients with at least one contact with MHS in 2013. Costs of services were estimated using a microcosting method. We defined as high cost (HC) those patients whose community mental health services costs place them in the top decile of the cost distribution. The predictors of costs were investigated using multiple linear regression. RESULTS: The overall costs borne for 7601 patients were 17 million , with HC accounting for 87% of costs and 73% of services. Compared with the rest of the patients, HC were younger, more likely to be male, to have a diagnosis of psychosis, and longer and more intensive MHS utilization. In multiple linear regression, younger age, longer duration of contact with MHS, psychosis, bipolar disorder, personality disorder, depression, dementia and Italian citizenship accounted for 20.7% of cost variance. CONCLUSION: Direct mental health costs are concentrated among a small fraction of patients who receive intensive socio-rehabilitation in community services. One limitation includes the unavailability of hospital costs. Our methodology is replicable and useful for national and cross-national benchmarking.
Asunto(s)
Servicios Comunitarios de Salud Mental , Costos de la Atención en Salud , Trastornos Mentales , Salud Mental/economía , Rehabilitación Psiquiátrica/economía , Trastornos Psicóticos , Adulto , Anciano , Servicios Comunitarios de Salud Mental/economía , Servicios Comunitarios de Salud Mental/estadística & datos numéricos , Estudios Transversales , Demencia/economía , Demencia/epidemiología , Femenino , Humanos , Italia/epidemiología , Modelos Lineales , Masculino , Trastornos Mentales/clasificación , Trastornos Mentales/economía , Trastornos Mentales/epidemiología , Persona de Mediana Edad , Prevalencia , Trastornos Psicóticos/economía , Trastornos Psicóticos/epidemiología , Estudios RetrospectivosRESUMEN
BACKGROUND: Immunoglobulin light chain (AL) amyloidosis can be treated with high-dose melphalan and autologous stem cell transplantation (HDM/SCT). Risk factors for infections may include hyposplenism, hypogammaglobulinemia, treatment-related neutropenia, melphalan-induced mucositis, and nosocomial exposures. METHODS AND DESIGN: A review of 493 patients with AL amyloidosis undergoing treatment with HDM/SCT from August 1994 to August 2009 was performed. The objectives were to determine the rate and types of infections following HDM/SCT, to identify factors associated with microbiologically documented infections, and to assess the contribution of infections to all-cause treatment-related mortality (TRM; defined as deaths within 100 days of SCT). RESULTS: Microbiologically documented infections after HDM/SCT occurred in 24% (n = 119) of patients. TRM was 10% (n = 48) overall, and 21% (n = 25) in patients who had a documented infection. Thus, the relative risk of TRM in a patient with a documented infection was 3.42 (95% confidence interval [CI] 2.02-5.79). Infections were caused by gram-positive bacteria in 51%, anaerobic bacteria in 16%, gram-negative bacteria in 13%, and fungi in 9% of cases. Serum creatinine >2 mg/dL was associated with increased risk of post-SCT infection (38% vs. 21%, P = 0.0007) with an odds ratio of 2.27 (95% CI 1.40-3.68). No significant association for infection was found for age, gender, cardiac involvement, prior steroid therapy, dose of melphalan, multiorgan involvement, days to neutrophil engraftment, or dose of CD34 + cells infused. CONCLUSION: Serum creatinine >2 mg/dL is a risk factor for infections in patients with AL amyloidosis undergoing HDM/SCT. The relative risk of TRM in a patient with a documented infection was increased >3-fold. A broad spectrum of infections, similar to that in other SCT patients, is seen in this population in the early post-SCT period.
Asunto(s)
Amiloidosis/terapia , Infecciones Bacterianas/etiología , Melfalán/administración & dosificación , Micosis/etiología , Agonistas Mieloablativos/administración & dosificación , Complicaciones Posoperatorias , Trasplante de Células Madre/efectos adversos , Anciano , Anciano de 80 o más Años , Infecciones Bacterianas/diagnóstico , Infecciones Bacterianas/mortalidad , Terapia Combinada , Infección Hospitalaria/etiología , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Cadenas Ligeras de Inmunoglobulina , Masculino , Persona de Mediana Edad , Micosis/diagnóstico , Micosis/mortalidad , Factores de Riesgo , Trasplante AutólogoAsunto(s)
ADN Polimerasa Dirigida por ADN/genética , Enfermedades Gastrointestinales/congénito , Enfermedades Gastrointestinales/genética , Seudoobstrucción Intestinal/complicaciones , Seudoobstrucción Intestinal/genética , Enfermedades Musculares/congénito , Enfermedades Musculares/genética , Mutación Missense/genética , Deficiencia de Citocromo-c Oxidasa/genética , Deficiencia de Citocromo-c Oxidasa/fisiopatología , Análisis Mutacional de ADN , ADN Polimerasa gamma , ADN Mitocondrial/metabolismo , Resultado Fatal , Enfermedades Gastrointestinales/diagnóstico , Tracto Gastrointestinal/metabolismo , Tracto Gastrointestinal/patología , Tracto Gastrointestinal/fisiopatología , Marcadores Genéticos/genética , Predisposición Genética a la Enfermedad/genética , Genotipo , Humanos , Recién Nacido , Seudoobstrucción Intestinal/diagnóstico , Masculino , Debilidad Muscular/congénito , Debilidad Muscular/genética , Debilidad Muscular/fisiopatología , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Músculo Esquelético/fisiopatología , Músculo Liso/metabolismo , Músculo Liso/patología , Músculo Liso/fisiopatología , Enfermedades Musculares/diagnóstico , Insuficiencia Respiratoria/genética , Insuficiencia Respiratoria/fisiopatología , SíndromeRESUMEN
The role of adiponectin and epicardial adipose tissue in coronary artery disease (CAD) is a subject of debate. Whether plasma adiponectin concentration in the coronary circulation is locally modulated by the epicardial fat is still unexplored. We evaluated the hypothesis whether intracoronary plasma adiponectin levels are related to adiponectin expression in epicardial adipose tissue in vivo in patients with CAD and without CAD (non-CAD). We examined 12 patients with CAD who required CABG and 10 patients with non-CAD who underwent cardiac surgery for valve replacement. Plasma levels of adiponectin were measured in peripheral vein circulation and in left coronary artery (LCA) during coronary angiography. Epicardial adipose tissue biopsy for adiponectin protein extraction was performed during cardiac surgery in both CAD and non-CAD subjects. Adiponectin protein expression in epicardial adipose tissue was lower in patients with CAD than in those with non-CAD (0.45+/-0.4 vs. 1.1+/-1.0, p<0.05). LCA plasma adiponectin levels significantly correlated with epicardial adipose tissue adiponectin protein expression (r=0.68, p=0.02) in all subjects. Peripheral adiponectin levels and epicardial fat adiponectin protein expression were the best correlates of LCA adiponectin, r (2)=0.49, p<0.01, p<0.05, respectively). Our study showed that intracoronary adiponectin levels reflect systemic adiponectin levels. Epicardial adipose tissue could partially contribute to adiponectin levels in the coronary circulation.
Asunto(s)
Adiponectina/metabolismo , Tejido Adiposo/metabolismo , Enfermedad Coronaria/metabolismo , Vasos Coronarios/metabolismo , Adiponectina/sangre , Anciano , Angiografía Coronaria , Puente de Arteria Coronaria , Enfermedad Coronaria/sangre , Enfermedad Coronaria/cirugía , Estudios Transversales , Femenino , Enfermedades de las Válvulas Cardíacas/sangre , Enfermedades de las Válvulas Cardíacas/metabolismo , Enfermedades de las Válvulas Cardíacas/cirugía , Implantación de Prótesis de Válvulas Cardíacas , Humanos , Masculino , Persona de Mediana Edad , Válvula Mitral/cirugíaRESUMEN
1. Angiotensin (Ang) II plays a major role in vascular remodelling. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are involved in the tissue remodelling processes. The aim of the present study was to investigate whether AngII modulates TIMP-2 expression in rat aortic smooth muscle cells in vivo. 2. Angiotensin II (200 ng/kg per min, s.c.) or AngII + losartan (10 mg/kg per day, s.c.) or normal saline was administered continuously by osmotic minipumps to Sprague-Dawley rats for 1 week. In addition, the effect of endogenous AngII on TIMP-2 expression was evaluated in renovascular hypertensive rats (two kidney, one clip (2K1C) and one kidney, one clip (1K1C) models). Control rats (sham 2K1C and sham 1K1C rats) underwent sham-clipping of the left renal artery. At the end of the treatment, plasma renin activity was measured by radioimmunoassay, aortic TIMP-2 mRNA expression was evaluated by real-time polymerase chain reaction and/or northern blotting and protein expression was evaluated by immunohistochemistry. Systolic blood pressure (SBP) was measured twice a week by the tail-cuff method. 3. Exogenous AngII administration produced the expected increase in SBP (P = 0.02) compared with the control saline-treated group. The increase in SBP was abolished in AngII + losartan-treated rats. Administration of AngII caused a significant increase in TIMP-2 expression (P = 0.01) in rat aortic smooth muscle cells that was abolished in AngII + losartan-treated rats. In renovascular hypertensive rats, SBP was higher (P < 0.0001) in 2K1C and 1K1C rats compared with the corresponding sham-operated rats. Plasma renin activity was higher (P < 0.01) in 2K1C rats compared with the other groups. The expression of TIMP-2 was significantly (P < 0.05) increased only in 2K1C rats. 4. Our in vivo data demonstrate that exogenous and endogenous AngII increases TIMP-2 expression in rat aortic smooth muscle cells. This effect is not dependent on the AngII-induced increase in blood pressure and is mediated by angiotensin AT1 receptors.
Asunto(s)
Angiotensina II/farmacología , Presión Sanguínea/fisiología , Músculo Liso Vascular/metabolismo , Inhibidor Tisular de Metaloproteinasa-2/biosíntesis , Animales , Aorta/citología , Aorta/efectos de los fármacos , Aorta/metabolismo , Northern Blotting , Células Cultivadas , Hipertensión Renovascular/patología , Inmunohistoquímica , Masculino , Músculo Liso Vascular/efectos de los fármacos , ARN Mensajero/biosíntesis , ARN Mensajero/aislamiento & purificación , Ratas , Ratas Sprague-Dawley , Renina/sangre , Sistema Renina-Angiotensina/efectos de los fármacos , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
The aim of this work was to carry out a cost evaluation of the home care programme for terminally ill cancer patients run by the Istituto Oncologico Romagnolo (I.O.R.) in the areas of Forlì, Cesena, Ravenna and Rimini (Romagna, Italy). To determine effective home care direct costs, we first selected 1 week of care as an observation unit. We then proceeded to assess the medical and nursing care units together with the clinical protocols administered for each patient. The Karnofsky Performance Status (KPS) was also assessed weekly. In this way, we calculated care costs for each patient and for each week as the sum of medical costs, nursing costs, treatment costs and other costs. A consecutive series of 574 patients were involved in the study from 1 April 1994 to 31 March 1995. A total of 5164 patient-weeks of care was provided, with an average cost per week of 177.6 Ecu. This weekly cost increased in the last 100 days of life (week -15 = 179.5 Ecu; week -8 = 188.3 Ecu; week -2 = 221.0 Ecu; P < 0.001). When single components were analysed in relation to total cost (treatment protocols, physician and nursing care) the increased global cost was found to be mainly attributable to the intensification in nursing care (21.8% of costs in week -15 vs 27.3% of costs in week -2). Examination of the relation between the cost of 1 week of care and KPS values clearly shows that healthcare costs increased as KPS decreased (from 152.2 Ecu with KPS > or = 60 to 292.6 Ecu with KPS < or = 20; P < 0.001). Home care costs were also seen to vary with some clinical characteristics and symptoms present when patients entered the study: asthenia, anorexia, nausea/vomiting, bedsores. Given the good results of home care for cancer patients in terms of quality of life, this method of cost accounting for home-care providers can help to monitor the rising cost of assistance and confirm the cost effectiveness of this type of care.
Asunto(s)
Costos de la Atención en Salud , Servicios de Atención de Salud a Domicilio/economía , Cuidados Paliativos al Final de la Vida/economía , Neoplasias/economía , Cuidados Paliativos/economía , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Costos y Análisis de Costo , Femenino , Cuidados Paliativos al Final de la Vida/métodos , Humanos , Italia , Modelos Lineales , Masculino , Persona de Mediana Edad , Neoplasias/fisiopatología , Neoplasias/terapia , Cuidados Paliativos/métodos , Estudios Prospectivos , Enfermo TerminalRESUMEN
The constant increase in the non-military use of nuclear energy in various fields induced this study of one particular field: the aero industry. Alitalia has been using gammagraphy and industrial metallography for nondestructive testing for over 20 years. Workers exposed to ionising radiations at work are protected by precisely detailed standards based on extremely rigorous national and international legislation. The health and protection of these workers is entrusted to a Company Doctor and a Qualified Specialist. The latter is thought to be indispensable since he is responsible for primary preventions as well as prompt diagnosis.